Liver

Ocaliva, or Obeticholic Acid, emerges as a promising therapy for non-alcoholic steatohepatitis (NASH), focusing on improving liver fibrosis in this severe condition. The importance of targeting fibrosis is underscored by NASH’s chronic progression towards cirrhosis and liver failure. Insights from pivotal studies illustrate Ocaliva’s effectiveness, highlighting its dosage-related benefits and manageable safety profile. Discover how […]